Related Experiment Video
Updated: Mar 24, 2026
The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
Control of Methicillin-Resistant Staphylococcus aureus Pneumonia Utilizing TLR2 Agonist Pam3CSK4
Yi-Guo Chen1, Yong Zhang2,3, Lin-Qiang Deng1
1Medical Laboratory, Jiangxi Provincial People's Hospital, and Institute of Immunotherapy, Nanchang University, Nanchang, Jiangxi 330008 China.
Abstract:
The spread of methicillin-resistant Staphylococcus aureus (MRSA) is a critical health issue that has drawn greater attention to the potential use of immunotherapy. Toll-like receptor 2 (TLR2), a pattern recognition receptor, is an essential component in host innate defense system against S. aureus infection. However, little is known about the innate immune response, specifically TLR2 activation, against MRSA infection. Here, we evaluate the protective effect and the mechanism of MRSA murine pneumonia after pretreatment with Pam3CSK4, a TLR2 agonist. We found that the MRSA-pneumonia mouse model, pretreated with Pam3CSK4, had reduced bacteria and mortality in comparison to control mice. As well, lower protein and mRNA levels of TNF-α, IL-1β and IL-6 were observed in lungs and bronchus of the Pam3CSK4 pretreatment group. Conversely, expression of anti-inflammatory cytokine IL-10, but not TGF-β, increased in Pam3CSK4-pretreated mice. Our additional studies showed that CXCL-2 and CXCL1, which are necessary for neutrophil recruitment, were less evident in the Pam3CSK4-pretreated group compared to control group, whereas the expression of Fcγ receptors (FcγⅠ/Ⅲ) and complement receptors (CR1/3) increased in murine lungs. Furthermore, we found that increased survival and improved bacterial clearance were not a result of higher levels of neutrophil infiltration, but rather a result of enhanced phagocytosis and bactericidal activity of neutrophils in vitro and in vivo as well as increased robust oxidative activity and release of lactoferrin. Our cumulative findings suggest that Pam3CSK4 could be a novel immunotherapeutic candidate against MRSA pneumonia.
Insights
Pam3CSK4, a Toll-like receptor 2 (TLR2) agonist, shows promise in treating methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Pretreatment reduced MRSA bacteria and mortality by enhancing neutrophil function, not just infiltration.
Area of Science:
- Immunology
- Infectious Diseases
- Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health threat, necessitating novel therapeutic strategies.
- Toll-like receptor 2 (TLR2) plays a crucial role in innate immunity against Staphylococcus aureus infections.
- The specific innate immune response, particularly TLR2 activation, against MRSA infection remains incompletely understood.
Purpose of the Study:
- To investigate the protective effects and underlying mechanisms of Pam3CSK4, a TLR2 agonist, in a murine model of MRSA pneumonia.
- To elucidate the impact of TLR2 activation on inflammatory cytokine profiles and immune cell responses during MRSA infection.
Main Methods:
- Establishment of a MRSA-induced pneumonia mouse model.
- Administration of Pam3CSK4 as a pretreatment agent.
- Analysis of bacterial load, mortality rates, and inflammatory cytokine expression (TNF-α, IL-1β, IL-6, IL-10) in lung and bronchus tissues.
- Assessment of neutrophil recruitment (CXCL-2, CXCL1) and the expression of Fcγ receptors and complement receptors.
- Evaluation of neutrophil phagocytosis, bactericidal activity, oxidative activity, and lactoferrin release.
Main Results:
- Pam3CSK4 pretreatment significantly reduced bacterial burden and mortality in MRSA-pneumonia mice compared to controls.
- Reduced levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and increased levels of the anti-inflammatory cytokine IL-10 were observed in the lungs of Pam3CSK4-treated mice.
- Neutrophil recruitment was not elevated, but phagocytosis, bactericidal activity, oxidative activity, and lactoferrin release by neutrophils were enhanced.
- Expression of Fcγ receptors and complement receptors increased in the lungs of treated mice.
Conclusions:
- Pam3CSK4 pretreatment confers protection against MRSA pneumonia by modulating the innate immune response.
- The protective mechanism involves enhanced neutrophil function, including phagocytosis and bactericidal activity, rather than solely increased neutrophil infiltration.
- Pam3CSK4 represents a potential novel immunotherapeutic candidate for combating MRSA pneumonia.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Atypical Pneumonia
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...